Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab

BACKGROUND: Induction therapy with interleukin-2 receptor antagonists has been established as an effective immunosuppressive strategy in the management of heart transplant (HTx) recipients. We compared outcomes following HTx in patients receiving basiliximab, daclizumab, or no induction therapy. MET...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Circ J
Huvudupphovsmän: Martin, Spencer T., Kato, Tomoko S., Farr, Maryjane, McKeen, Jaclyn T., Cheema, Faisal, Ji, Mengxi, Ross, Alexandra, Yerebakan, Halit, Naka, Yoshifumi, Takayama, Hiroo, Restaino, Susan, Mancini, Donna, Schulze, P. Christian
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967552/
https://ncbi.nlm.nih.gov/pubmed/25501951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circj.CJ-14-0718
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk